Qiming Venture Partners adds two IPOs in a week, taking 2026 total to nine

The dual IPOs of Nasn Intelligent Tech and Attovia Therapeutics underscore a significant trend in Asian venture capital: the successful nurturing and public market realization of deep tech and biotech innovations. Nasn’s listing, particularly, highlights China’s strategic push for self-reliance in critical automotive components like brake-by-wire systems, essential for the burgeoning smart driving and autonomous vehicle sectors. Its expansion into robotics and low-altitude aircraft motion control also signals a broader ambition to leverage core technological capabilities across multiple frontier industries, positioning it as a key player in China’s advanced manufacturing landscape. This reflects a maturation of the Chinese tech ecosystem, moving beyond internet services to foundational hardware and AI-driven solutions.

Attovia’s Nasdaq listing, meanwhile, demonstrates the global appeal and potential of Asian-backed biopharmaceutical innovation, particularly in addressing unmet medical needs through advanced platforms like Attobody. Qiming’s consistent support for both companies from early stages to IPO reflects a robust investment thesis focused on foundational innovation and long-term growth. The success of these diverse portfolio companies indicates a healthy appetite in public markets for companies solving complex technical challenges, reinforcing Asia’s growing role as a hub for both industrial and life science breakthroughs.